Triple Negative Breast Cancer Drug Development Summit

This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.

Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summit has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

This is the industry's definitive conference specifically dedicated to advancing the development of both monotherapy and combinatorial
therapies to improve the current standard of care for patients with TNBC.

Join leading experts from CytoDyn, Zenith Epigenetics, Oncorus, University of Pittsburgh and more who are identifying specific molecular targets, such as immune checkpoint modulators, intra-nuclear targets, intracellular targets, and cell surface targets, to limit the progression and metastasis of this invasive tumor and improve patient outcomes.

Whether you are developing a TROP2-ADC, a PARP inhibitor, a viral immunotherapy or a cancer vaccine for treating TNBC, this dedicated digital meeting is your opportunity to discuss novel, cutting edge targeted therapies in TNBC and get a full picture of the clinical landscape.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

URLs:
Website: https://go.evvnt.com/729098-0?pid=176 
Tickets: https://go.evvnt.com/729098-1?pid=176 
Brochure: https://go.evvnt.com/729098-2?pid=176 

Prices:
Conference Only (Drug Developer Pricing): USD 1999.00,
Conference Only (Service Provider Pricing): USD 2499.00,
Conference Only (Academic Pricing): USD 1799.00

Speakers: Alison L. Hannah, Senior Vice President and Chief Medical Officer, CytomX Therapeutics, Angus Sinclair, VP Immuno-Oncology, IGM Biosciences, Brian J Czerniecki, Chair Department of Breast Oncology, Moffitt Cancer Center, Eric Campeau, Senior Director - Translational Medicine, Zenith Epigenetics, Eva Gonzalez- Suarez, Principal Investigator, IDIBELL, Eytan Ruppin, Chief, Cancer Data Science Lab, NCI, NIH, Iman El-Hariry, Chief Medical Officer, Erytech, John Goldberg, Senior Vice President – Clinical Development, Oncorus, Leisha Emens, Professor of Medicine, University of Pittsburgh Department of Medicine, Matthew Ellis, Professor and Director, Lester and Sue Smith Breast Center, Baylor College of Medicine, Maureen Lane, Translational Scientific Lead, Bristol Myers-Squibb, Naoto T. Ueno, Professor of Medicine, MD Anderson Cancer Centre, Neelima Vidula, Breast Medical Oncologist, Massachusetts General Hospital, Sandra Dunn, Chief Executive Officer, Phoenix Molecular Designs, Scott Kelly, Chief Medical Officer, Cytodyn, Shaveta Vinayak, Assistant Professor, University of Washington, Sima Lev, Principal Investigator, Weizmann Institute of Science, Stephen Ethier, Professor of Pathology Medical, University of South Carolina, Timothy Yap, Associate Professor, Investigational Cancer Therapeutics, MD Anderson Cancer Centre

Time: 08:00 to 16:00